Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer

Prostate cancer management is complicated by extreme disease heterogeneity, which is further limited by availability of prognostic biomarkers. Recognition of prostate cancer as a genetic disease has prompted a focus on the nuclear genome for biomarker discovery, with little attention given to the mitochondrial genome. While it is evident that mitochondrial DNA (mtDNA) mutations are acquired during prostate tumorigenesis, no study has evaluated the prognostic value of mtDNA variation. Here we used next-generation sequencing to interrogate the mitochondrial genomes from prostate tissue biopsies and matched blood of 115 men having undergone a radical prostatectomy for which there was a mean of 107 months clinical follow-up. We identified 74 unique prostate cancer specific somatic mtDNA variants in 50 patients, providing significant expansion to the growing catalog of prostate cancer mtDNA mutations. While no single variant or variant cluster showed recurrence across multiple patients, we observe a significant positive correlation between the total burden of acquired mtDNA variation and elevated Gleason Score at diagnosis and biochemical relapse. We add to accumulating evidence that total acquired genomic burden, rather than specific mtDNA mutations, has diagnostic value. This is the first study to demonstrate the prognostic potential of mtDNA mutational burden in prostate cancer.

[1]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[2]  M. Haigis,et al.  Mitochondria and Cancer , 2016, Cell.

[3]  F. Montorsi,et al.  Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. , 2016, European urology.

[4]  C. Haiman,et al.  No Association between the Mitochondrial Genome and Prostate Cancer Risk: The Multiethnic Cohort , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[5]  E. Chan,et al.  Spectrum of mitochondrial genomic variation and associated clinical presentation of prostate cancer in South African men , 2015, The Prostate.

[6]  T. Tammela,et al.  Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening , 2015, Clinical Cancer Research.

[7]  Stephanie M. Tortorella,et al.  Introduction to the molecular basis of cancer metabolism and the Warburg effect , 2015, Molecular Biology Reports.

[8]  Michael Fraser,et al.  Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. , 2015, Urologic oncology.

[9]  A. Kim.  Mitochondrial DNA Somatic Mutation in Cancer , 2014, Toxicological research.

[10]  Bin Tean Teh,et al.  Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer , 2014, eLife.

[11]  A. Salas,et al.  No association between typical European mitochondrial variation and prostate cancer risk in a Spanish cohort , 2014, Journal of Human Genetics.

[12]  Michael J. Barry,et al.  Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. , 2014, JAMA.

[13]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[14]  Johan Lindberg,et al.  The mitochondrial and autosomal mutation landscapes of prostate cancer. , 2013, European urology.

[15]  H. D. de Koning,et al.  Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.

[16]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[17]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[18]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[19]  F. Kronenberg,et al.  Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. , 2010, American journal of human genetics.

[20]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[21]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[22]  H. D. de Koning,et al.  Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer , 2009, British Journal of Cancer.

[23]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[24]  E. Siegel,et al.  Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells , 2008, The Prostate.

[25]  E. Rochtchina,et al.  Prevalence of mitochondrial DNA haplogroups in an Australian population , 2006, Internal medicine journal.

[26]  E. Condom,et al.  Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients. , 2006, Mutation research.

[27]  F. Marshall,et al.  North American white mitochondrial haplogroups in prostate and renal cancer. , 2006, The Journal of urology.

[28]  David C. Miller,et al.  Prostate carcinoma presentation, diagnosis, and staging , 2003, Cancer.

[29]  Junjian Z. Chen,et al.  Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. , 2002, Cancer research.

[30]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[31]  D. Turnbull,et al.  Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA , 1999, Nature Genetics.

[32]  E. Shoubridge,et al.  Distribution and threshold expression of the tRNA(Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). , 1992, American journal of human genetics.

[33]  M. King,et al.  Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. , 1989, Science.

[34]  Michael J. Wilson,et al.  Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. , 2008, American journal of clinical pathology.

[35]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.

[36]  Shamkant B. Navathe,et al.  MITOMAP: a human mitochondrial genome database--1998 update , 1998, Nucleic Acids Res..